skip to content

Phase III IMpassion130 study showed Roche's Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.